RITUXIMAB THERAPY IN PEDIATRIC PATIENTS WITH THE TAFRO SYNDROME, A VARIANT OF IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 225; Pres time: Sep 17, 2026; Location: Exhibition Area; "The two patients with severe baseline IL-6 elevations also received tocilizumab. Children/Adolescents with iMCD-TAFRO demonstrate heterogeneous clinical phenotypes, which may complicate prompt diagnosis and treatment. Rituximab may provide effective, durable treatment responses, potentially avoiding the need for prolonged anti-IL-6 therapy."
Clinical • Fibrosis • Gastroenterology • Hematological Disorders • Human Immunodeficiency Virus • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Inflammation • Nephrology • Pediatrics • Rare Diseases • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura
|
|
Janki Patel; Kala Kamdar; Olive Eckstein; Zachary Prudowsky; Jennifer Kogan; Hana Paek; Choladda Curry; Andrea Marcogliese; Tarek Elghetany; Kenneth Mcclain; Carl Allen; Nader El-Mallawany
|